Monte Rosa Therapeutics (GLUE) Receivables - Other (2022 - 2026)

Monte Rosa Therapeutics' Receivables - Other history runs 5 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 227.34% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $4.6 million, a 227.34% increase from a year earlier, with the FY2025 full-year figure at $4.6 million, up 1485.54% from the prior year.
• Receivables - Other climbed to $4.6 million in Q1 2026 per GLUE's latest filing, from -$365000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $5.0 million in Q3 2025 and bottomed at -$422000.0 in Q4 2024.
• The 5-year median for Receivables - Other is $842000.0 (2024), against an average of $1.5 million.
• Across the five-year window, Receivables - Other jumped 3260.0% in 2023 and slumped 225.6% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $10000.0 in 2022, then soared by 3260.0% to $336000.0 in 2023, then slumped by 225.6% to -$422000.0 in 2024, then advanced by 13.51% to -$365000.0 in 2025, then jumped by 1362.74% to $4.6 million in 2026.
• Per Business Quant, the three latest GLUE Receivables - Other figures stand at $4.6 million (Q1 2026), -$365000.0 (Q4 2025), and $5.0 million (Q3 2025).